Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472941 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KDM4ESPHK1HRH3 | |
| SCHEMBL13416615 | 0.85 | — | — | |
| SCHEMBL15723668 | 0.85 | — | — | |
| SCHEMBL13416618 | 0.84 | KDM4E (0.49) | ALDH1A1KDM4ESPHK2SPHK1GAA | |
| SCHEMBL24682861 | 0.83 | HRH3 (0.50) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL16480464 | 0.78 | ALDH1A1 (0.66) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL9893059 | 0.75 | MAPK1 (0.56) | ALDH1A1KDM4ESPHK2SPHK1 | |
| SCHEMBL4839388 | 0.75 | SPHK2 (0.52) | ALDH1A1KDM4ESPHK2SPHK1CYP1A2 | |
| SCHEMBL4839403 | 0.75 | SPHK2 (0.52) | ALDH1A1KDM4ESPHK2SPHK1CYP1A2 | |
| SCHEMBL4848314 | 0.75 | SPHK2 (0.52) | ALDH1A1KDM4ESPHK2SPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | ALDH1A1 147/4885KDM4E 1970/4885SPHK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.